PCSK9 and familial hypercholesterolemia: PCSK9 has been reported as a therapeutic target for patients with dyslipidemia or hypercholesterolemia, and overexpression of PCSK9 is associated with oncogenesis and enhances the malignant phenotypes of CRC with APC/KRAS mutations.